Until a relevant regulatory agency has approved a Cara Therapeutics product for a specific disease or population, any scientific publication or presentation regarding such disease or population is not to be considered instructions on the use of the Cara Therapeutics product or clinical development candidate.
If you have any questions about our papers, please contact us.
Pruritus in Dialysis Dependent Chronic Kidney Disease
Topf J, et al. Kidney Medicine. 2022;4(8): 100512.
Fishbane S, et al. Kidney Medicine. 2022;4(8): 100513.
Shirazian S, et al. Presented at the National Kidney Foundation Spring Clinical Meetings, 2022.
Weiner D, et al. Presented at the European Renal Association – European Dialysis and Transplant Association Congress, 2021.
Fishbane S, et al. New England Journal of Medicine. 2020;382: 222-232
Fishbane S, et al. Kidney International Reports. 2020;5: 600-610
Pruritus in Non-Dialysis Dependent Chronic Kidney Disease
Yosipovitch G, et al. Presented at the American Academy of Dermatology Annual Meeting, 2020
Pruritus in Atopic Dermatitis
Guttman-Yassky E, et al. Presented at the American Academy of Dermatology Annual Meeting, 2022
Kim B, et al. Presented at the European Academy of Dermatology and Venereology Congress, 2021
Pruritus in Notalgia Paresthetica
Kim B, et al. Presented at the European Academy of Dermatology and Venereology Congress, 2022
Kappa Opioid Receptor Agonism with Difelikefalin
Shram M, et al. Clinical and Translational Science. 2022;15: 535-547
Viscusi E, et al. Clinical and Translational Science. 2021;14: 1886-1893
Kappa Opioid Receptor Agonism with Difelikefalin
Bacci E, et al. Journal of the American Academy of Dermatology International. 2022;8: 94-101
Vernon M, et al. Journal of Patient-Reported Outcomes. 2021;5: 1-12
Vernon M, et al. Journal of the American Academy of Dermatology. 2021;84: 1132-1134